Statera Biopharma, Inc. (OTCPK:STAB) entered into a letter of intent to acquire Worksite Labs on March 15, 2023. Worksite reported the revenue of $50 million for the period ended 2022. Completion of the Proposed Transaction is subject to, among other matters, the completion of due diligence, the negotiation of definitive agreements providing for the Proposed Transaction, and satisfaction of a number of conditions negotiated therein, including, but not limited to regulatory approvals including FINRA, and board of directors' and shareholder approvals.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0007 USD | 0.00% | 0.00% | +16.67% |
2023 | Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. | CI |
2023 | Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
+16.67% | 50.81K | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- STAB Stock
- News Statera Biopharma, Inc.
- Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs.